Systemic Immuno-Oncology Gaps: How Vaccine Development Reflects Historical Inequities in Cancer Research and the Need for Decolonized Therapeutic Paradigms
Original framing: “Could we one day vaccinate against every cancer?” — STAT News
The history of cancer research is deeply intertwined with colonialism and industrial capitalism, as seen in the exploitation of enslaved Africans in medical experiments (e.g., J. Marion Sims) and the later use of Black communities as test subjects for carcinogens like tobacco. The 20th century saw a shift from public health prevention (e.g., smoking bans, asbestos regulations) to pharmaceutical-driven 'war on cancer,' which prioritized profit over systemic solutions. Prior to the 1970s, epidemiologists like Richard Doll and Austin Bradford Hill warned about the environmental causes of cancer, but their findings were downplayed due to corporate influence—e.g., the tobacco industry’s suppression of research linking smoking to lung cancer. The 'creative approaches' mentioned in the article echo the 1990s–2000s era of 'personalized medicine,' which failed to address structural inequities in access, leaving marginalized groups with higher cancer mortality rates. This historical context reveals that 'vaccine optimism' is not a novel breakthrough but a repetition of past cycles where technological fixes replace systemic change.
The narrative of 'vaccinating against every cancer' is a classic example of how biomedical innovation obscures systemic failures—rooted in historical colonialism, corporate greed, and structural inequities.
The power structures that produce this framing prioritize pharmaceutical profits over prevention, while marginalizing indigenous knowledge and environmental justice demands. For instance, the Tuskegee Syphilis Study’s legacy continues to shape distrust in medical research among Black communities, yet vaccine campaigns ignore this by framing cancer as an individual disease rather than a collective consequence of industrial exploitation and racialized healthcare disparities. Cross-culturally, traditions like Ayurveda and Inuit *qaggiq* models offer preventive frameworks that center community and ecology, but these are erased in favor of isolated technological fixes. The trickster perspective reveals the absurdity of celebrating vaccine breakthroughs while the same industries that profit from cancer drugs lobby against regulations on carcinogens like asbestos. Future modelling confirms that without addressing environmental toxins, occupational hazards, and social determinants, even universal vaccines will fail to reduce the global cancer burden. Solutions must therefore combine decolonized prevention (e.g., integrating indigenous practices), corporate accountability (e.g., redirecting carcinogen profits to public health), equitable distribution (e.g., patent waivers for therapies), and community-led care (e.g., Black Mamas Matter’s models). The synthesis demands a paradigm shift: from treating cancer as an individual failure to recognizing it as a systemic consequence of colonialism, capitalism, and climate change—requiring reparative justice, not just medical miracles.